Taishi Hirai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taishi Hirai has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
J. Aaron Grantham
Division of Cardiology, Department of Medicine University of Washington Seattle Washington USA
12 shared publicationsWilliam Lombardi
Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA
12 shared publicationsJames Sapontis
Monash Heart Melbourne Australia
10 shared publications- Adam C. Salisbury
Saint Luke's Mid America Heart Institute Kansas City Missouri USA
9 shared publications Dimitri Karmpaliotis
Morristown Medical Center Morristown New Jersey USA
9 shared publicationsWilliam J. Nicholson
Emory University Atlanta Georgia USA
9 shared publications
Latest Publications
- 1 March 2026
- Published by Edizioni Minerva Medica in Minerva Cardiology and Angiology
- Vol. 74 (1)
A prospective, randomized comparison of workhorse guidewires for bifurcation percutaneous coronary intervention
Despite the significant improvement in guidewire technology, in-vivo comparison of workhorse guidewires is lacking. This study aims to assess the feasibility of randomized data collection regarding the wiring time and its variability among three guidewires: Sion Blue, Minamo, and Runthrough, and to identify key lesion characteristics for future guidewire research. 45 patients were randomized between February of 2023 and May 2024. Patients undergoing elective percutaneous coronary intervention (PCI) to a bifurcation lesion requiring two guidewires were included. The wiring time was defined from when the tip of the guidewire at the end of the guide catheter until the advancement to the distal target vessel. The mean wiring time was 55.3 seconds for side branch and 95.8 seconds for main branch. The wiring time was similar for both side-branch wiring (Sion Blue 65.9±79.5, Minamo 41.2±33.4, Runthrough 57.6±88, P=0.65) and the main branch wiring (Sion Blue 44.8±38.9, Minamo 123.8±189.4, Runthrough 119.1±183.6, P=0.3). Use of the torque device, guidewire reshaping, or switching to a second guidewire were uncommon. Lesions requiring longer wiring time had severe stenosis (>90%), severe calcification, or tortuosity. The median crossing time was longer when recrossing stent struts, especially during two-stent strategy (>130 seconds). Prospective data collection assessing the difference of wiring time as a clinical endpoint is feasible. Our study results can form a basis for future studies comparing different guidewires.
- 1 March 2026
- Published by Edizioni Minerva Medica in Minerva Cardiology and Angiology
- Vol. 74 (1)
A prospective, randomized comparison of workhorse guidewires for bifurcation percutaneous coronary intervention
Despite the significant improvement in guidewire technology, in-vivo comparison of workhorse guidewires is lacking. This study aims to assess the feasibility of randomized data collection regarding the wiring time and its variability among three guidewires: Sion Blue, Minamo, and Runthrough, and to identify key lesion characteristics for future guidewire research. 45 patients were randomized between February of 2023 and May 2024. Patients undergoing elective percutaneous coronary intervention (PCI) to a bifurcation lesion requiring two guidewires were included. The wiring time was defined from when the tip of the guidewire at the end of the guide catheter until the advancement to the distal target vessel. The mean wiring time was 55.3 seconds for side branch and 95.8 seconds for main branch. The wiring time was similar for both side-branch wiring (Sion Blue 65.9±79.5, Minamo 41.2±33.4, Runthrough 57.6±88, P=0.65) and the main branch wiring (Sion Blue 44.8±38.9, Minamo 123.8±189.4, Runthrough 119.1±183.6, P=0.3). Use of the torque device, guidewire reshaping, or switching to a second guidewire were uncommon. Lesions requiring longer wiring time had severe stenosis (>90%), severe calcification, or tortuosity. The median crossing time was longer when recrossing stent struts, especially during two-stent strategy (>130 seconds). Prospective data collection assessing the difference of wiring time as a clinical endpoint is feasible. Our study results can form a basis for future studies comparing different guidewires.
- Open Access
- 19 December 2025
- Published by Elsevier in JACC: Asia
- Vol. 6 (2) , 141-143
Revisiting the Proton Pump Inhibitor–Clopidogrel Conundrum
- 19 December 2025
- Published by Elsevier in JACC: Asia
- Vol. 6 (2) , 141-143
Open AccessRevisiting the Proton Pump Inhibitor–Clopidogrel Conundrum
- 12 August 2025
- Published by Elsevier in Interventional Cardiology Clinics
- Vol. 14 (4) , 499-506
Complex and High-Risk Intervention via Upper Extremity Access
- 12 August 2025
- Published by Elsevier in Interventional Cardiology Clinics
- Vol. 14 (4) , 499-506
Complex and High-Risk Intervention via Upper Extremity Access
- 13 August 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (4) , 755-758
Use of dual‐lumen microcatheter pullback injection in complex percutaneous coronary intervention
Dual‐lumen microcatheters (DLMC) are utilized in challenging wiring scenarios as well as for contrast and medication injections. Nonetheless, lesion characterization remains extremely challenging in many cases. We describe a DLMC‐facilitated technique which can assist in locating the distal anastomosis while navigating an occluded bypass graft during retrograde chronic total occlusion recanalization, as well as in the differential diagnosis of abrupt vessel closure. This “DLMC Pullback Injection” technique is performed by injecting contrast through the over‐the‐wire port of the DLMC, while the latter is quickly pulled back across the region of interest in a dynamic fashion. We believe this technique has the potential to solve challenging scenarios and to enrich the complex percutaneous coronary intervention operator's armamentarium.
- 13 August 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (4) , 755-758
Use of dual‐lumen microcatheter pullback injection in complex percutaneous coronary intervention
Dual‐lumen microcatheters (DLMC) are utilized in challenging wiring scenarios as well as for contrast and medication injections. Nonetheless, lesion characterization remains extremely challenging in many cases. We describe a DLMC‐facilitated technique which can assist in locating the distal anastomosis while navigating an occluded bypass graft during retrograde chronic total occlusion recanalization, as well as in the differential diagnosis of abrupt vessel closure. This “DLMC Pullback Injection” technique is performed by injecting contrast through the over‐the‐wire port of the DLMC, while the latter is quickly pulled back across the region of interest in a dynamic fashion. We believe this technique has the potential to solve challenging scenarios and to enrich the complex percutaneous coronary intervention operator's armamentarium.
- 24 July 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (3) , 444-450
Optimal timing of staged percutaneous coronary intervention after subintimal tracking and re‐entry: Rationale and design of the subintimal tracking and re‐entry with deferred stenting study
Background: Ten to fifteen percent of chronic total occlusion (CTO) percutaneous coronary interventions (PCIs) are unsuccessful in contemporary practice. Subintimal tracking and re‐entry (STAR) (one form of “investment procedure”) with staged reattempt and stenting may further increase the ultimate success and safety of CTO as a bailout strategy. The optimal timing for staged stenting after STAR is unknown.Methods and Results: We designed a six‐center, prospective randomized trial with a planned enrollment of 150 patients where STAR is utilized in case of impending failure. The primary aim is to evaluate the optimal timing of the staged PCI after STAR by randomizing the timing to earlier (5–7 weeks) versus later (12–14 weeks) staged PCI. The primary endpoint of the study is the technical success rate of the staged procedure. The secondary endpoints include: (1) the rate of thrombolysis in myocardial infarction 3 flow at the start of staged intervention, (2) rate of partial technical and procedural success of the staged procedure, (3) rate of in‐hospital and 12‐month major cardiac and cerebrovascular adverse events, and (4) change in patient‐reported quality at 30 days, 6 months, and 12 months assessed by Seattle Angina Questionnaire.Conclusion: This study will ascertain the optimal timing of staged stenting after bail‐out STAR approach in contemporary CTO PCI (ClinicalTrials.gov NCT05089864).
- 24 July 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (3) , 444-450
Optimal timing of staged percutaneous coronary intervention after subintimal tracking and re‐entry: Rationale and design of the subintimal tracking and re‐entry with deferred stenting study
Background: Ten to fifteen percent of chronic total occlusion (CTO) percutaneous coronary interventions (PCIs) are unsuccessful in contemporary practice. Subintimal tracking and re‐entry (STAR) (one form of “investment procedure”) with staged reattempt and stenting may further increase the ultimate success and safety of CTO as a bailout strategy. The optimal timing for staged stenting after STAR is unknown.Methods and Results: We designed a six‐center, prospective randomized trial with a planned enrollment of 150 patients where STAR is utilized in case of impending failure. The primary aim is to evaluate the optimal timing of the staged PCI after STAR by randomizing the timing to earlier (5–7 weeks) versus later (12–14 weeks) staged PCI. The primary endpoint of the study is the technical success rate of the staged procedure. The secondary endpoints include: (1) the rate of thrombolysis in myocardial infarction 3 flow at the start of staged intervention, (2) rate of partial technical and procedural success of the staged procedure, (3) rate of in‐hospital and 12‐month major cardiac and cerebrovascular adverse events, and (4) change in patient‐reported quality at 30 days, 6 months, and 12 months assessed by Seattle Angina Questionnaire.Conclusion: This study will ascertain the optimal timing of staged stenting after bail‐out STAR approach in contemporary CTO PCI (ClinicalTrials.gov NCT05089864).
- 31 May 2024
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 70, 64-68
The effect of standardization of insertion and removal of percutaneous left ventricular assist device
- 31 May 2024
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 70, 64-68
The effect of standardization of insertion and removal of percutaneous left ventricular assist device
- Open Access
- 18 October 2023
- Published by Elsevier in Journal of Cardiology
- Vol. 83 (4) , 272-279
Practice differences and knowledge gaps in complex and high-risk interventions between Japan and the USA: A case-based discussion
- 18 October 2023
- Published by Elsevier in Journal of Cardiology
- Vol. 83 (4) , 272-279
Open AccessPractice differences and knowledge gaps in complex and high-risk interventions between Japan and the USA: A case-based discussion
- 7 September 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (5) , 814-822
Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study
Background: Indications and outcomes for percutaneous ventricular assist device (pVAD) use in surgically ineligible patients undergoing percutaneous coronary intervention (PCI) remain poorly characterized.Aims: We sought to describe the use and timing of pVAD and outcome in surgically ineligible patients.Methods: Among 726 patients enrolled in the prospective OPTIMUM study, clinical and health status outcomes were assessed in patients who underwent pVAD‐assisted PCI and those without pVAD.Results: Compared with patients not receiving pVAD (N = 579), those treated with pVAD (N = 142) more likely had heart failure, lower left ventricular ejection fraction (30.7 ± 13.6 vs. 45.9 ± 15.5, p < 0.01), and higher STS 30‐day predicted mortality (4.2 [2.1−8.0] vs. 3.3 [1.7−6.6], p = 0.01) and SYNTAX scores (36.1 ± 12.2, vs. 31.5 ± 12.1, p < 0.01). While the pVAD group had higher in‐hospital (5.6% vs. 2.2%, p = 0.046), 30‐day (9.0% vs. 4.0%, p = 0.01) and 6‐month (20.4% vs. 11.7%, p < 0.01) mortality compared to patients without pVAD, this difference appeared to be largely driven by significantly higher mortality among the 20 (14%) patients with unplanned pVAD use (30% in‐hospital mortality with unplanned PVAD vs. 1.6% with planned, p < 0.01; 30‐day mortality, 38.1% vs. 4.5%, p < 0.01). The degree of 6‐month health status improvement among survivors was similar between groups.Conclusion: Surgically ineligible patients with pVAD‐assisted PCI had more complex baseline characteristics compared with those without pVAD. Higher mortality in the pVAD group appeared to be driven by very poor outcomes by patients with unplanned, rescue pVAD.
- 7 September 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (5) , 814-822
Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study
Background: Indications and outcomes for percutaneous ventricular assist device (pVAD) use in surgically ineligible patients undergoing percutaneous coronary intervention (PCI) remain poorly characterized.Aims: We sought to describe the use and timing of pVAD and outcome in surgically ineligible patients.Methods: Among 726 patients enrolled in the prospective OPTIMUM study, clinical and health status outcomes were assessed in patients who underwent pVAD‐assisted PCI and those without pVAD.Results: Compared with patients not receiving pVAD (N = 579), those treated with pVAD (N = 142) more likely had heart failure, lower left ventricular ejection fraction (30.7 ± 13.6 vs. 45.9 ± 15.5, p < 0.01), and higher STS 30‐day predicted mortality (4.2 [2.1−8.0] vs. 3.3 [1.7−6.6], p = 0.01) and SYNTAX scores (36.1 ± 12.2, vs. 31.5 ± 12.1, p < 0.01). While the pVAD group had higher in‐hospital (5.6% vs. 2.2%, p = 0.046), 30‐day (9.0% vs. 4.0%, p = 0.01) and 6‐month (20.4% vs. 11.7%, p < 0.01) mortality compared to patients without pVAD, this difference appeared to be largely driven by significantly higher mortality among the 20 (14%) patients with unplanned pVAD use (30% in‐hospital mortality with unplanned PVAD vs. 1.6% with planned, p < 0.01; 30‐day mortality, 38.1% vs. 4.5%, p < 0.01). The degree of 6‐month health status improvement among survivors was similar between groups.Conclusion: Surgically ineligible patients with pVAD‐assisted PCI had more complex baseline characteristics compared with those without pVAD. Higher mortality in the pVAD group appeared to be driven by very poor outcomes by patients with unplanned, rescue pVAD.
- 20 July 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (4) , 774-775
“Crossing the invisible”
Key Points: Using the septal collaterals without angiographic connection during retrograde CTO PCI was associated with high collateral channel crossing rate (>80%). Two predicators for channel crossing failure were shorter posterior descending artery (less than 2/3 of the distance to cardiac apex) and well developed non‐septal collateral. Further studies focusing on retrograde channel selection could improve the success rate and safety of retrograde CTO PCI.
- 20 July 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (4) , 774-775
“Crossing the invisible”
Key Points: Using the septal collaterals without angiographic connection during retrograde CTO PCI was associated with high collateral channel crossing rate (>80%). Two predicators for channel crossing failure were shorter posterior descending artery (less than 2/3 of the distance to cardiac apex) and well developed non‐septal collateral. Further studies focusing on retrograde channel selection could improve the success rate and safety of retrograde CTO PCI.